Ainos, Inc. announced its plan to conduct a clinical study in Taiwan for VELDONA, its very low-dose interferon alpha, targeting Sjögren's syndrome. The study is slated to take place at Taipei Medical University-Shuang Ho Hospital, with regulatory approvals aimed for completion in Q4 2024. This initiative follows eight prior clinical trials conducted in the U.S. for VELDONA in Sjögren's syndrome.
Prior Phase 3 studies demonstrated positive benefits, specifically showing an increase in unstimulated whole saliva secretion. The company is pursuing a capital-efficient strategy by conducting these clinical trials within Taiwan. This approach allows Ainos to advance its therapeutic pipeline while managing development costs effectively.
This move aims to position VELDONA as a potential treatment for a rare autoimmune disease with limited existing options. The initiation of this study is a key step in Ainos' strategy to develop and commercialize its VELDONA platform for human health applications. It underscores the company's commitment to addressing unmet medical needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.